- The P-III DELOS study involves assessing of Idebenone (900 mg/day) vs PBO in 64 patients with Duchenne muscular dystrophy (DMD) for 52wks. & P-II DELPHI study with 2-year extension study (DELPHI-E). SYROS study involves assessing of Idebenone (900 mg/day) in 18 patients under Expanded Access Programs (EAPs) who completed the DELOS study
- The P-III Delos study resulted in meeting 1EP as slow loss of respiratory function. The Syros study resulted in long-term & consistent long-term reduction in rate of respiratory function & maintained up-to 6yrs.
- Idebenone is a synthetic benzoquinone & a cofactor for the enzyme NAD(P)H: quinone oxidoreductase (NQO1) capable of stimulating mitochondrial electron transport, reducing and scavenging reactive oxygen species (ROS) and supplementing cellular energy levels
Click here to read full press release/ article | Ref: Santhera | Image: Twitter